Delving into the Latest Updates on Aspirin with Synapse

Overview

Basic Info

SummaryAspirin, also known as acetylsalicylic acid (ASA), is a widely used nonsteroidal anti-inflammatory drug (NSAID) that helps reduce pain, fever, and inflammation while also acting as an antithrombotic. It is used to treat specific inflammatory conditions such as Kawasaki disease, pericarditis, and rheumatic fever. Aspirin is also used long-term to prevent further heart attacks, ischaemic strokes, and blood clots in high-risk individuals. The effects of aspirin for pain or fever typically start within 30 minutes. Aspirin works similarly to other NSAIDs but also suppresses the normal functioning of platelets. Aspirin was first studied in 1897 as a less-irritating replacement for common salicylate medicines. By 1899, Bayer had named it "Aspirin" and sold it worldwide. Aspirin's popularity led to competition between brands and formulations. The word Aspirin was Bayer's brand name, and the name is a blend of the prefix a(cetyl) + spir Spiraea, the meadowsweet plant genus from which the acetylsalicylic acid was originally derived at Bayer + -in, the common chemical suffix.

Drug Type

Small molecule drug

Synonyms

Acetylsalicylic acid, ASA, Asiirin

+ [51]

Target

COX-1 x COX-2

Mechanism

COX-1 inhibitors(Cyclooxygenase-1 inhibitors), COX-2 inhibitors(Cyclooxygenase-2 inhibitors)

Therapeutic Areas

Immune System DiseasesInfectious DiseasesNervous System Diseases+ [8]

Active Indication

Peripheral Arterial DiseaseMucocutaneous Lymph Node SyndromeMigraine Disorders+ [14]

Inactive Indication

Acute Coronary SyndromeAcute low back painAnemia, Sickle Cell+ [17]

Originator Organization

Bayer Healthcare LLC

Active Organization

Shanxi Fushenggong Pharmaceutical Group Co., Ltd.

Bayer Yakuhin Ltd.

Bayer AG

+ [5]

Inactive Organization

Ipsen SA

Sclnow Biotechnology Co., Ltd.

Hesperos, Inc.

+ [1]

Drug Highest PhaseApproved

First Approval Date

US (25 Jun 1965),

Migraine Disorders

RegulationOrphan Drug (US)

Login to view timeline

Structure/Sequence

Molecular FormulaC9H8O4

InChIKeyBSYNRYMUTXBXSQ-UHFFFAOYSA-N

CAS Registry50-78-2

A Randomized, Open Label, Semi-replicate Crossover Pharmacokinetic Study to Compare the Bioavailability of a Single Oral Dose of Aspirin® 81mg Quick Chews® and a Single Oral Dose of Acetylsalicylic Acid 81mg Chewable Tablets for Testing of Bioequivalence Under Fasting Conditions in Healthy Adult Subjects

In this study, researchers want to learn if 2 different forms of acetylsalicylic acid (ASA) chewable tablets will have the same effect in the body. For this, they compared the blood levels of a new form of ASA chewable tablet, which is manufactured at a different site, with an approved ASA chewable tablet, on an empty stomach in healthy participants. This is done as part of the regulatory requirement for the marketing approval of the new ASA chewable tablet.
The study treatment, ASA, is an antiplatelet drug. It works by making the blood thinner and stopping the blood from clotting.
In this study, participants will be healthy and will not benefit from taking ASA chewable tablets. However, the study will provide information on how the new ASA chewable tablet, which is manufactured at a different site, has an effect on the body.
The main purpose of this study is to compare blood levels of the new ASA chewable tablet with the approved ASA chewable tablet when taken as a single dose on an empty stomach.
For this, the researchers will analyze:
* Area under the curve (AUC): a measure of the total amount of ASA in participants' blood over time
* Maximum observed concentration (Cmax): the highest amount of ASA in participants' blood after a single dose without food
This study will have 3 treatment periods of 4 days each. In each period, participants will take either the new or approved ASA chewable tablet on an empty stomach according to the order assigned to them. The 2 treatment sequences in this study are:
New chewable tablet, approved chewable tablet, new chewable tablet
Approved chewable tablet, new chewable tablet, approved chewable tablet
Each participant will be in the study for around 7 weeks, which includes:
* a visit within 21 days of the first period to confirm if the participant can take part in the study
* hospital stay of around 2 days in each period, during which, participants will take their assigned treatment, and have blood tests to check for drug levels
* a gap of 1 week after taking the treatment in each period
During the study, the doctors and their study team will:
* measure the level of the study treatment by taking blood samples
* check participants' health by performing urine tests, checking vital signs and checking heart health using an electrocardiogram (ECG)
* ask the participants questions about how they are feeling and what adverse events they are having
An adverse event is any medical problem that a participant has during a study. The study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment.
As this study is conducted in healthy participants who will not benefit from the treatment, access to the treatment after the study is not planned.

Start Date11 Aug 2025

Sponsor / Collaborator

Bayer AG

ChiCTR2400093812

/ SuspendedNot ApplicableIIT

Aspirin for the prevention of preeclampsia based on platelet aggregation rate - a multi-center, stepped-wedge cluster, randomized controlled trial

Start Date01 Jul 2025

Sponsor / Collaborator

Obstetrics and Gynecology Hospital of Fudan University

100 Clinical Results associated with Aspirin

Login to view more data

100 Translational Medicine associated with Aspirin

Login to view more data

100 Patents (Medical) associated with Aspirin

Login to view more data

94,104

Literatures (Medical) associated with Aspirin

31 Dec 2025·ANNALS OF MEDICINE

Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis

Review

Author: Qiu, Kaijie ; Wang, Jie ; Gan, Yichao ; Wang, Haibiao ; Jiang, Keting ; Zhou, Songsheng ; Wang, Donghuan

BACKGROUND:

Numerous meta-analyses have identified various risk factors for hepatocellular carcinoma (HCC), prompting a comprehensive study to synthesize evidence quality and strength.

METHODS:

This umbrella review of meta-analyses was conducted throughout PubMed, EMBASE, Web of Science, and Cochrane Database of Systematic Reviews. Evidence strength was evaluated according to the evidence categories criteria.

RESULTS:

We identified 101 risk factors throughout 175 meta-analyses. 31 risk factors were classified as evidence levels of class I, II, or III. HBV and HCV infections increase HCC risk by 12.5-fold and 11.2-fold, respectively. These risks are moderated by antiviral treatments and virological responses but are exacerbated by higher HBsAg levels, anti-HBc positivity, and co-infection. Smoking, obesity, non-alcoholic fatty liver disease, diabetes, low platelet, elevated liver enzymes and liver fluke infection increase HCC risk, while coffee consumption, a healthy diet, and bariatric surgery lower it. Medications like metformin, glucagon-like peptide-1 receptor agonists (GLP-1 RAs), aspirin, statins, and selective serotonin reuptake inhibitors reduce HCC risk, while acid suppressive agents, particularly proton pump inhibitors, elevate it. Blood type O reduces the risk of HCC, while male gender and older age increase the risk.

CONCLUSIONS:

HBV and HCV are major HCC risk factors, with risk mitigation through antiviral treatments. Lifestyle habits such as smoking and alcohol use significantly increase HCC risk, highlighting the importance of cessation. Certain drugs like aspirin, statins, GLP-1 RAs, and metformin may reduce HCC occurrence, but further research is needed to confirm these effects.

01 Dec 2025·CHILDS NERVOUS SYSTEM

Bedside transfontanelle drain placement reduces the need for operative intervention in infants with subdural fluid collections

Article

Author: Hankinson, Todd C ; Wilkinson, C Corbett ; Pazniokas, Julia ; Alexander, Allyson L ; Harris, William ; Samples, Derek C ; Handler, Michael H ; Alshareef, Mohammed

OBJECTIVE:

Subdural fluid collection is a common neurosurgical condition in the pediatric population. Patients requiring surgical intervention have historically been managed with subdural drains, subdural-subgaleal shunting, subdural-peritoneal shunting, and mini-craniotomies. An alternative procedure for patients with an open anterior fontanelle is bedside transfontanelle drainage. This study aims to evaluate the efficacy of the transfontanelle angiocatheter drain placement including complications and the need for any further surgery.

METHODS:

We performed a single-center retrospective review of all patients who underwent placement of transfontanelle drain to treat subdural fluid collections from January 2013 to June 2023. Data points collected included demographics, comorbidities, mechanism of subdural collection, neurologic status on presentation, subdural size, amount of drainage, complications, and need for further intervention.

RESULTS:

We identified 28 patients who underwent bedside transfontanelle subdural angiocatheter placement between January 2013 and June 2023. The patient age range was 0-11 months (avg 3.96). Twenty-three patients were male (82%). Nineteen patients (68%) had new seizures on presentation or during hospitalization. Eighteen patients (64%) suffered non-accidental trauma. The subdural on the side of the drainage ranged from 4 to 18 mm in size. On average, a total of 590 mL (22-1648) of fluid was drained over 3.5 (1-9) days. One medically complex patient on aspirin for cardiac comorbidities had post-procedural complication of new hemorrhage and one patient developed meningitis. Nineteen patients did not require any further treatment. Six patients underwent subsequent subdural-peritoneal shunting, two required subsequent placement of surgical subdural drains, and one underwent bilateral burr hole craniotomies with subdural drain placement. Patients who suffered NAT were more likely to not need further intervention than those with other mechanisms of subdural fluid collections.

CONCLUSIONS:

This retrospective review demonstrates that bedside transfontanelle drain placement is an effective practice to reduce the need for operative intervention in infants with an open anterior fontanelle. The procedure can be performed expeditiously in the emergency room, ICU, or floor setting without the need for general anesthesia. While future larger prospective studies are warranted, our series documented this practice to be performed safely.

01 Dec 2025·European Journal of Trauma and Emergency Surgery

Post-operative complications associated with the pre-operative use of Aspirin in patients undergoing surgery for hip or femoral fracture: a meta-analysis

Review

Author: Yang, Jun ; Cheng, Zhonghua ; Huang, Lin ; Xue, Wei ; Feng, Fei ; Wu, Chenhuan ; Song, Junlai

BACKGROUND:

The number of patients with hip and femoral fractures is increasing and is expected to further increase in upcoming years due to the ageing population and the life expectancy of the general population. In this analysis, we aimed to systematically assess the post-operative complications associated with the pre-operative use of Aspirin in patients undergoing surgery for hip or femoral fracture.

METHODS:

Common online databases: Google Scholar, Web of Science, MEDLINE, Cochrane database, EMBASE ( www.sciencedirect.com ), and http://www.

CLINICALTRIALS:

gov were searched for English-based studies which reported post-operative outcomes in patients with versus without the use of Aspirin prior to surgery for hip or femoral fracture. The endpoints of this analysis included cerebro-vascular attack, acute coronary syndrome/cardiovascular complications, hematoma, deep venous thrombosis, pulmonary embolism, patients requiring blood transfusion, bleeding events, and in-hospital mortality. RevMan software 5.4 was the statistical software used for this meta-analysis. Risk ratio (RR) with 95% confidence intervals (CI) was used to represent the post-analytical result.

RESULTS:

A total number of 2823 participants were included in this analysis whereby 821 were assigned to Aspirin prior to surgery. Results of this analysis showed that post-operatively the risk of cerebrovascular attack (RR: 1.62, 95% CI 0.29-9.20; P = 0.58), cardiovascular complication (RR: 1.86, 95% CI 0.62-5.52; P = 0.27), pulmonary embolism (RR: 2.45, 95% CI 0.77-7.77; P = 0.13), bleeding events (RR: 1.24, 95% CI 0.39-3.96; P = 0.71), and in-hospital mortality (RR: 0.95, 95% CI 0.47-1.91; P = 0.89) were not significantly higher in those patients who were and who were not taking Aspirin pre-operatively. The risk of deep venous thrombosis (RR: 1.82, 95% CI 0.23-14.60; P = 0.57), hematoma formation (RR: 1.57, 95% CI 0.11-21.49; P = 0.74) and patients requiring blood transfusion post-operatively (RR: 1.22, 95% CI 0.99-1.52; P = 0.07) were not significantly different in patients who were on Aspirin and those who were not on Aspirin pre-operatively.

CONCLUSION:

The post-operative complications associated with the pre-operative use of Aspirin in patients undergoing surgery for hip or femoral fracture were apparently not significantly different when compared to patients who were not on Aspirin. Therefore, Aspirin should not be considered an absolute contraindication in patients undergoing surgery for hip or femoral fracture. Hence, an early or emergency surgery for hip or femoral neck fracture in patients on Aspirin therapy should apparently not pose any problem. Further larger trials should be able to confirm this hypothesis.

432

News (Medical) associated with Aspirin

05 Feb 2025

·www.mobihealthnews.com

Q&A: Sera Prognostics on preventing preterm birth using protein markers

During the JPM Healthcare Conference in San Francisco, Zhenya Lindgardt, CEO of Sera Prognostics, sat down with MobiHealthNews to discuss the company’s focus on preventing preterm birth, a leading cause of neonatal mortality, by identifying protein markers that indicate risk. MobiHealthNews: How does Sera work in women's health? Zhenya Lindgardt: Sera is a unique company. Any executive dreams of achieving impact, and for a mom of three, leaving my kids, it needs to be for an amazing mission, and it is. We're focused on pregnancy that affects half of the population, and in any given year, all of the women of childbearing age may become pregnant, and we are focused on preventing preterm birth, which is not as well known as I would like. It is a very prevalent condition. Unfortunately, one out of 10 babies will be born preterm, which is defined as before 37 weeks of gestation and with significant health complications that are associated with that. Obviously, the health complications are a lot worse if it's a really premature baby that is born, for example, before 28 weeks, versus a baby that is born at 36 weeks, for example. But, those who are born before 28 weeks may spend three or four months in the NICU. Actually, about a third of mortality in neonates is driven by prematurity. So, it's a leading cause of death for babies. So, it's definitely worthwhile for society to find new solutions to screen for potential preterm birth. MHN: What is Sera offering regarding preventing preterm birth? Lindgardt: Sera has mapped over 300 proteins that get expressed by the placenta throughout pregnancy, and we pinpointed markers that specifically point to the risk of preterm birth. Specific proteins, IBP4 to SHBG, have been shown and get expressed through weeks 18 to 20 of pregnancy, and the ratio between the two of them can help us definitively pinpoint whether the woman is at higher risk for preterm birth. Specifically, it's a ratio between the two proteins, not the absolute quantity of these proteins, because absolute quantity varies dramatically across the phenotype. No two people are the same, but the ratio of these two proteins is directionally very telling and helps stratify women into those who will be at higher risk and those who are not at higher risk. If you ask me what that threshold is, we validated a threshold of two times the average rate of preterm birth. So, in our test, when we look at the ratio of these two proteins, we draw the line and tell the physician that if the woman is at two times the risk, she is at higher risk for preterm birth. If she is not, she is not. MHN: What would providers do with that information? Lindgardt: We turned to the Society for Maternal-Fetal Medicine and key opinion leaders who deal with higher-risk pregnancies, and they helped design an intervention that includes three components: low-dose aspirin (81mg aspirin), vaginal progesterone applied daily and care management – a fancy name for a structured nurse call every week, which, frankly, is better care. So, that's a three-prong bundle that we tested in three clinical trials: prevent, avert and prime. It just concluded very successfully. It was stopped in the interim. About a year ago, we got a letter unexpectedly from DSMB [Data Safety and Monitoring Board] that oversaw our trial. They saw the interim data and said, "You can stop the trial. The results look amazing." By the time we stopped enrollment, we already enrolled 5,000 patients. So just last week, the abstract from that study was published in the pregnancy journal. We hit both primary and co-primary endpoints, which were the health of the baby and hospital length of stay. So the health of the baby improved by 20% as measured by neonatal mortality and morbidity index, which is a four-point scale – four being, unfortunately, the death of the baby, and one being some light complications for the baby. So, a 20% improvement means that the complications were a lot less severe. Why? Because stratifying the pregnancy early into higher risk versus not higher risk, and deploying the intervention extended gestation and made the baby healthier at birth by exchanging gestation, and therefore the baby gets out of the hospital sooner because it's healthier. So the second co-primary endpoint was the length of stay in the hospital, and that was improved dramatically also. MHN: How have providers responded to the study? Lindgardt: The reception has been very curious and positive, because physicians do not have any tools. They want to be able to screen for preterm birth, because 50% of moms who end up giving birth prematurely don't have any other risk factors. So, there is no way for physicians to spot them and to predict, and this is the most litigated profession, unfortunately, in healthcare, because, of course, as you said, it's a tragedy if you lose a baby or if you have complications for the baby. So, they are appropriately keen to get verified, robust tools to spot who that woman is at risk that they should pay attention to. The average appointment length is 15 minutes, and they need to stratify their resources to the mom who needs it the most – but how do they know which mom needs it the most? That's where the test comes in. So, they're very keen to get more tools. That's why this is so powerful, because you can predict something is going to go wrong and ameliorate its effects before the physician diagnoses a condition or a complication.

Clinical Result

05 Feb 2025

·www.drugs.com

Inflammatory Bowel Disease Tied to Higher Risk for Heart Disease

WEDNESDAY, Feb 5, 2025 -- Male patients with inflammatory bowel disease (IBD) face a higher risk for ischemic heart diseases (IHDs), according to a study published in the March issue of the International Journal of Cardiology Cardiovascular Risk and Prevention . Noa Cohen-Heyman and Gabriel Chodick, Ph.D., both from Tel Aviv University in Israel, investigated the association between IBD and long-term risk for IHD. The analysis included 14,768 patients diagnosed with IBD (from January 1990 to July 2021; 6,144 with ulcerative colitis and 8,624 with Crohn disease) and 120,338 matched individuals without IBD. The researchers found that during a mean follow-up of 10.5 years, 1.9 percent of participants with IBD and 1.0 percent of the reference group experienced a composite outcome of IHD, myocardial infarction, undergoing percutaneous coronary intervention, or undergoing coronary artery bypass grafting (composite hazard ratio [HR], 1.98). A higher risk for IHD was associated with IBD only in male patients (HR, 1.82), whereas a negative association was seen among female patients (HR, 0.72). When limiting analyses to patients with Crohn disease, patients with ulcerative colitis, patients on steroids, and patients on immunosuppressants, results were similar. "High-risk individuals could be evaluated for early biomarkers predictive of future IHD, such as high-sensitive cardiac troponin, potentially making them candidates for preventive interventions, including daily aspirin administration," the authors write. Abstract/Full Text Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical Result

04 Feb 2025

·www.drugs.com

Many Americans Misguided On Daily Aspirin, Survey Finds

TUESDAY, Feb. 4, 2025 -- Many Americans don’t see anything wrong with taking daily low-dose aspirin, even though experts have concluded its risks outweigh its benefits, a new survey has found. Nearly half (48%) of people incorrectly think that the benefits of taking low-dose aspirin daily to reduce the risk of heart attack or stroke outweigh the risks, according to the survey from the Annenberg Public Policy Center of the University of Pennsylvania. “Habits backed by conventional wisdom and the past advice of health care providers are hard to break,” Kathleen Hall Jamieson , the center's director, said in a news release. “Knowing whether taking a low-dose aspirin daily is advisable or not for you is vital health information,” she added. For years, healthy seniors were advised to take low-dose aspirin to reduce heart attack and stroke risk. The rationale was that aspirin acts as a blood thinner, reducing the risk that a blood clot could cause a heart attack or stroke by clogging an artery. But in 2019, the leading heart groups -- the American College of Cardiology and the American Heart Association -- reversed that recommendation in a set of new guidelines. The groups concluded that daily aspirin for healthy seniors 70 and older wasn’t worth the risk of gastrointestinal bleeding. "If you’re over 70, taking aspirin to prevent a first heart attack or stroke could do more harm than good," the AHA now says on its website. Aspirin still is recommended for people with diagnosed heart disease who don’t have an increased risk of bleeding. This updated guidance has failed to break through decades of advice supporting daily low-dose aspirin, the poll found. Nearly 1 in 5 U.S. adults who have no personal or family history of heart problems report routinely taking low-dose aspirin. According to survey results: Younger adults were more likely than older folks to correctly report that the risks of aspirin outweigh the benefits, the survey showed. About 29% of 18- to 29-year-olds with no personal or family history of heart disease correctly said the risks of daily aspirin outweigh benefits, compared with 11% of those 40 to 59 and 7% of those 60 and older, researchers found. That’s likely because the younger folks haven’t been exposed as much to the outdated guidance supporting aspirin use, researchers said. The survey involved 1,771 people polled Nov. 14 to 24, 2024, and has a margin of error of plus or minus 3.3 percentage points. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

AHAClinical StudyClinical Result

100 Deals associated with Aspirin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00109	Aspirin	A01AD05 B01AC06 N02BA01	DB00945

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Peripheral Arterial Disease	CN	Bayer Healthcare Co., Ltd.	05 Sep 2022
Coronary Artery Disease	US	Hesperos, Inc.	04 Sep 2015
Ischemic Attack, Transient	US	Hesperos, Inc.	04 Sep 2015
Ischemic stroke	US	Hesperos, Inc.	04 Sep 2015
Mucocutaneous Lymph Node Syndrome	JP	Bayer Yakuhin Ltd.	31 Oct 2005
Brain Ischemia	JP	Bayer Yakuhin Ltd.	22 Sep 2000
Thrombosis	JP	Bayer Yakuhin Ltd.	22 Sep 2000
Angina Pectoris	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Ankylosing Spondylitis	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Arthritis	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Gout	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Heart Valve Diseases	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Myocardial Infarction	CN	Shanxi Fushenggong Pharmaceutical Group Co., Ltd.	01 Jan 1998
Fever	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Pain	CN	Chengdu First Pharmaceutical Co. Ltd.	01 Jan 1981
Migraine Disorders	US	Bayer Healthcare LLC	25 Jun 1965

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Atrial Fibrillation	Phase 3	FR	Bayer AG	25 May 2020
COVID-19	Phase 3	BR	Bayer AG	21 Apr 2020
COVID-19	Phase 3	CA	Bayer AG	21 Apr 2020
COVID-19	Phase 3	CO	Bayer AG	21 Apr 2020
COVID-19	Phase 3	EC	Bayer AG	21 Apr 2020
COVID-19	Phase 3	EG	Bayer AG	21 Apr 2020
COVID-19	Phase 3	IN	Bayer AG	21 Apr 2020
COVID-19	Phase 3	NP	Bayer AG	21 Apr 2020
COVID-19	Phase 3	PK	Bayer AG	21 Apr 2020
COVID-19	Phase 3	PH	Bayer AG	21 Apr 2020

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ASH2024	Not Applicable	-	-	Aspirin (No BPA)	khfisrjwze(ufyfkuebtt) = iztrjukbiz wbvxueivlk (aatqoxohvw )	-	07 Dec 2024
NCT02044250 (HOST-EXAM Extended, Pubmed \| JAMA Cardiol)	Phase 4	Coronary Stenosis Maintenance	3,974	Clopidogrel	pumxfghssr(tuacxxreci): HR = 0.75 (95% CI, 0.53 - 1.04)	Positive	27 Nov 2024
				Aspirin
NCT02685748 (CTgov)	Phase 2/3	Schizophrenia \| Psychotic Disorders	60	Placebo	tckcukkwbt(jxuuqxjeld) = ydrbeyvsfa ouxgbzdvon (zrkzzbulnn, amgwdcnkdd - fhrnitzyee) View more	-	23 Sep 2024
NCT02467582 (SAKK 41/13, ESMO2024) Manual	Phase 3	Colonic Cancer Adjuvant PIK3CA Mutation	112	Aspirin 100mg daily for 3 years	rjqbtmpudw(livcgrnhnf) = otfvdneioj vvcdmssaqw (yeblooufvr, 80.1 - 93.3)	Positive	15 Sep 2024
				Placebo for 3 years	rjqbtmpudw(livcgrnhnf) = ydizzmbmlf vvcdmssaqw (yeblooufvr, 68.3 - 90.7)
AML-584 (SOHO2024)	Not Applicable	Leukemia	-	Aspirin users	mfwcuadism(fbvpsjfctn): OR = 0.72 (95% CI, 0.66 - 0.78) View more	Positive	04 Sep 2024
				Non-aspirin users
ESC2024	Not Applicable	-	-	Indobufen DAPT	ghauijmkwq(qgoeapaqek) = fxuctjizsc flqjfkagid (zehdvaxaaj ) View more	-	02 Sep 2024
				Aspirin DAPT	ghauijmkwq(qgoeapaqek) = fznlimtrwm flqjfkagid (zehdvaxaaj ) View more
ESC2024	Not Applicable	-	-	aspirin (< 5% ASCVD risk score)	jflobvbspw(bzwzzxpdeg) = bmtyomndug mzgctqrzzk (mbtfriamah )	-	01 Sep 2024
				aspirin (5 - 10% ASCVD risk score)	jflobvbspw(bzwzzxpdeg) = yxwgqfmjrv mzgctqrzzk (mbtfriamah )
NCT02697916 (ADAPTABLE, Pubmed \| JAMA Cardiol)	Not Applicable	Atherosclerosis	-	Aspirin 81 mg	rqgllmprwm(vetoueokpb) = sccavaihva nozzvgrfzt (rqshavilza ) View more	Positive	01 Sep 2024
				Aspirin 325 mg	rqgllmprwm(vetoueokpb) = tajiwmnhda nozzvgrfzt (rqshavilza ) View more
Pubmed Manual	Not Applicable	-	107,655	aspirin	smtuktjnil(opqyhmtkdj) = fwjvbzbbrz ctaexngqcw (atahotpjvs ) View more	Positive	01 Aug 2024
				Control	dfwwbqwoad(cvkhfwdhgk) = gkefhodple jaiwuajkxg (bphbahkucp, 2.31 - 3.58)
NCT02697916 (ADAPTABLE, Pubmed \| BMJ Open)	Not Applicable	Atherosclerosis	-	Low-dose aspirin (81 mg)	bvarxumcah(urkvgoftwi) = ehpiizldjr adsqzprcze (hilugrnbcf )	Positive	01 Aug 2024
				High-dose aspirin (325 mg)	bvarxumcah(urkvgoftwi) = pgrzwswcjq adsqzprcze (hilugrnbcf )